WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Dankeschön für die Rückmeldung! Ich wäre auch lieber mit positiveren News am Start, aber die Politik kocht derweil ihr eigenes Süppchen (und dürfte so einige Anleger verschrecken....).

👍🏼

Danke dir👌Die Infos sind immer super von dir!! Kann man nicht oft genug sage

Die Übersetzung lässt zu wünschen übrig, aber der Inhalt dürfte zu verstehen sein 🙃: https://inews.hket.com/article/3030553/%E3%80%90%E6%B8%AF%E8%82%A1%E5%B8%82%E6%B3%81%E3%80%91%E6%81%92%E7%94%9F%E6%8C%87%E6%95%B8%E5%8D%88%E5%BE%8C%E5%88%9D%E6%AE%B5%E5%81%8F%E8%BB%9F%E3%80%80%E5%89%B5%E7%A7%91%E7%B8%BE%E5%BE%8C%E5%8D%87%E4%B8%80%E6%88%90%E7%A0%B4%E9%A0%82%E3%80%81%E7%9C%BE%E5%AE%89%E5%9C%A8%E7%B6%AB%E8%B7%8C%E8%BF%9114-%EF%BC%88%E4%B8%8D%E6%96%B7%E6%9B%B4%E6%96%B0%EF%BC%89 WuXi Biologics (02269) fiel um mehr als 5 % auf bis zu RMB 116,5.  Das Zentralkomitee der Kommunistischen Partei Chinas und der Staatsrat haben am Mittwoch die "Umsetzungsrichtlinien für den Aufbau einer rechtsstaatlichen Regierung (2021-2025)" herausgegeben, in denen vorgeschlagen wird, die Gesetzgebung in wichtigen Bereichen wie nationale Sicherheit, technologische Innovation und Anti-Monopol sowie die Verbesserung des für die nationale Governance dringend benötigten Rechtssystems. Stärkung der Strafverfolgung im Lebensmittel- und Arzneimittelsektor.

Vaccine stocks continue to sell, two major new crown vaccine stocks in the United States are suffering https://m.hkej.com/landing/mobarticle2/id/2880537 ... In addition, the Central Committee of the Communist Party of China and the State Council issued the "Implementation Outline for Building a Government under the Rule of Law", proposing to increase law enforcement in key areas such as food and medicine, and other biotech stocks are also under pressure. ...

Major Pharmas Broadly Shorted; WUXI BIO Slumps Nearly 6% to Below 100MA http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/RUM.210812_111612/hk-stock-news ... WUXI APPTEC (02359 HK) and WUXI BIO (02269 HK) likewise slumped for two consecutive days, with the former dropping to as low as $155.5 at one point; last posted $156.2, down 4.5%. The latter, reaching below its 100MA at one point, lasted stood at $118.8, down 3.8%. ...

G Sachs Puts WUXI BIO on CL Buy, Downgrades 8 Pharmas Incl. FOSUN to Neutral with Broad TP Cut http://www.aastocks.com/en/stocks/news/aafn-con/now.1118781/latest-news While Goldman Sachs expected the Chinese healthcare sector is and will be regulated heavily in the foreseeable future, it noted significant improvement in regulatory consistency and transparency in the past five years. WUXI BIO (02269 HK) was restated at Buy and placed on the CL Buy, with target raised from $157.9 to $170.7. ...

The Hang Seng Index fluctuated and closed down 0.1% on Friday, and milk powder and pharmaceutical stocks were weak https://tw.stock.yahoo.com/news/%E6%81%86%E7%94%9F%E6%8C%87%E6%95%B8%E9%80%B1%E4%BA%94%E9%9C%87%E7%9B%AA%E6%94%B6%E8%B7%8C0-1-%E5%A5%B6%E7%B2%89%E8%88%87%E9%86%AB%E8%97%A5%E9%A1%9E%E8%82%A1%E7%96%B2%E5%BC%B1-090239868.html ...However, China’s continued intervention, milk powder stocks and pharmaceutical stocks suffered as a result, dragged down the pace of the Hang Seng Index’s rise, making it narrow on Friday The range fluctuated, and finally ended in black, continuing the previous day's decline.  ... China stated that the price of vaccines provided to developing countries would be one of the lowest, and pharmaceutical stocks fell, with vaccine stocks leading the decline. WuXi Biologics (2269 HK) fell 4.85%, the worst performance among the constituent stocks; Shanghai Fosun Pharma (2196 HK), which is a distributor of BNT vaccines, tumbled 10.3%, and Cansino (6185 HK), which develops local vaccines, closed 1.84% lower. However, the state-owned Sinopharm Holdings (1099 HK) edged up 0.48%.   ...

Hat wohl den Index erwischt. Nicht der schönste Bericht, aber zumindest eine Info: Vaccine pharmaceutical stocks fell collectively, and WuXi AppTech slumped over 9% https://news.stcn.com/sd/202108/t20210806_3516188.html

Vielen lieben Dank für die Rückmeldungen! Freut mich sehr! Soll aber niemanden davon abhalten, hier auch zu posten oder sich zu äußern. Habe heute noch keine News gefunden, warum WuXi deutlich nachgibt. Aber momentan sind Schwankungen in China ja etwas mehr an der Tagesordnung. Ein schönes Wochenende 🌞🙋🏼‍♀️

Dem schließe ich mich an 👍

@Summer.76: Danke für dein unermüdliches Posten. Dadurch dass quasi nur du schreibst bleibt dieses Forum auf jeden Fall sauber und informativ. LG & gerne weiter so. Hari

Hier ist die WuXi nicht direkt betroffen, aber durch die Partnerschaft an der Einreichung mit beteiligt. Anfang 2019 hatten WuXi Bio und CANbridge ihre Partnerschaft erweitert: die Rechte für die Therapien bleiben bei CANbridge, WuXi erhält dafür bspw. Voraus- und Meilensteinzahlungen. https://www.businesswire.com/news/home/20210802005178/en/CANbridge-Pharmaceuticals-CAN103-Investigational-New-Drug-Application-Accepted-by-China%E2%80%99s-National-Medical-Products-Administration CANbridge Pharmaceuticals Inc., ..., announced that the Investigational New Drug (IND) application for CAN103 has been accepted by the Chinese National Medical Products Administration (NMPA). CAN103 is an enzyme replacement therapy (ERT) being developed by CANbridge as part of its rare disease partnership with WuXi Biologics (2269 HK) for the long-term treatment of adults and children with Gaucher disease, Types I and III. ...

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate https://www.prnewswire.com/news-releases/wuxi-biologics-biosafety-testing-facility-received-second-ema-gmp-certificate-301345995.html

WuXi Biologics (02269 HK) plans to hold board meeting on August 23 to review interim results https://m.jrj.com.cn/madapter/hk/2021/07/29200733170972.shtml WuXi Biologics (02269 HK) announced that the company would like to hold a board meeting on August 23, 2021 (Monday), in order to (among other things) consider and approve the group's deadline to June 2021 Interim results and publication for the six months ended on the 30th.

How should investors choose between the high valuation of WuXi Biologics vs. the low valuation of Tigermed and Kanglong Chemical? https://hk.investing.com/news/stock-market-news/article-179297